TargetMol

LY3372689

Product Code:
 
TAR-T61661
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T61661-1mg1mg£174.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T61661-5mg5mg£329.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T61661-1mL1 mL * 10 mM (in DMSO)£346.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T61661-10mg10mg£486.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T61661-25mg25mg£744.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T61661-50mg50mg£1,002.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T61661-100mg100mg£1,324.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
LY3372689 is an orally active O-GlcNAcase (OGA) enzyme inhibitor for tau protein-based disorders including Alzheimer's disease.
CAS:
2241514-56-5
Molecular Weight:
383.44
Pathway:
Cytoskeletal Signaling
Purity:
0.9927
SMILES:
C(C=1SC(NC(C)=O)=NC1F)N2[C@@H](C)C[C@@H](OCC=3N=C(C)ON3)CC2
Target:
Microtubule Associated

References

Sergey Shcherbinin, et al. Brain target occupancy of LY3372689, an inhibitor of the O-GlcNAcase (OGA) enzyme: Translation from rat to human. Alzheimer's & Dementia. 2020;16(4):e040558 Nicolas Jacques Francois Dreyfus, et al. N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor. WO2018140299A1.